Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

Luna Colagrossi, Lucas E. Hermans, Romina Salpini, Domenico Di Carlo, Suzan D. Pas, Marta Alvarez, Ziv Ben-Ari, Greet Boland, Bianca Bruzzone, Nicola Coppola, Carole Seguin-Devaux, Tomasz Dyda, Federico Garcia, Rolf Kaiser, Sukran Köse, Henrik Krarup, Ivana Lazarevic, Maja M. Lunar, Sarah Maylin, Valeria MicheliOrna Mor, Simona Paraschiv, Dimitros Paraskevis, Mario Poljak, Elisabeth Puchhammer-Stöckl, François Simon, Maja Stanojevic, Kathrine Stene-Johansen, Nijaz Tihic, Pascale Trimoulet, Jens Verheyen, Adriana Vince, Snjezana Zidovec Lepej, Nina Weis, Tülay Yalcinkaya, Charles A.B. Boucher, Annemarie M.J. Wensing, Carlo F. Perno*, Valentina Svicher, HEPVIR working group of the European Society for translational antiviral research (ESAR)

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

37 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe'. Together they form a unique fingerprint.

Immunology and Microbiology